430 related articles for article (PubMed ID: 9371898)
1. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies.
Ryan R; Elkind A; Baker CC; Mullican W; DeBussey S; Asgharnejad M
Neurology; 1997 Nov; 49(5):1225-30. PubMed ID: 9371898
[TBL] [Abstract][Full Text] [Related]
2. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine.
Diamond S; Elkind A; Jackson RT; Ryan R; DeBussey S; Asgharnejad M
Arch Fam Med; 1998; 7(3):234-40. PubMed ID: 9596457
[TBL] [Abstract][Full Text] [Related]
3. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
4. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types.
Ashford E; Salonen R; Saiers J; Woessner M
Cephalalgia; 1998 Jun; 18(5):273-7. PubMed ID: 9673807
[TBL] [Abstract][Full Text] [Related]
5. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
[TBL] [Abstract][Full Text] [Related]
6. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
Winner P; Rothner AD; Wooten JD; Webster C; Ames M
Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents.
Winner P; Rothner AD; Saper J; Nett R; Asgharnejad M; Laurenza A; Austin R; Peykamian M
Pediatrics; 2000 Nov; 106(5):989-97. PubMed ID: 11061765
[TBL] [Abstract][Full Text] [Related]
8. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
Cady RK; McAllister PJ; Spierings EL; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2015 Jan; 55(1):88-100. PubMed ID: 25355310
[TBL] [Abstract][Full Text] [Related]
10. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
[TBL] [Abstract][Full Text] [Related]
11. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials.
Winner P; Landy S; Richardson M; Ames M
Clin Ther; 2005 Nov; 27(11):1785-94. PubMed ID: 16368449
[TBL] [Abstract][Full Text] [Related]
12. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
[TBL] [Abstract][Full Text] [Related]
13. Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine.
Natarajan S; Jabbour JT; Webster CJ; Richardson MS
Headache; 2004; 44(10):969-77. PubMed ID: 15546259
[TBL] [Abstract][Full Text] [Related]
14. Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine.
Peikert A; Becker WJ; Ashford EA; Dahlof C; Hassani H; Salonen RJ
Eur J Neurol; 1999 Jan; 6(1):43-9. PubMed ID: 10209349
[TBL] [Abstract][Full Text] [Related]
15. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
Rao AS; Gelaye B; Kurth T; Dash PD; Nitchie H; Peterlin BL
Headache; 2016 Feb; 56(2):331-40. PubMed ID: 26840902
[TBL] [Abstract][Full Text] [Related]
17. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.
Klassen A; Elkind A; Asgharnejad M; Webster C; Laurenza A
Headache; 1997; 37(10):640-5. PubMed ID: 9439085
[TBL] [Abstract][Full Text] [Related]
18. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
Schulman EA
Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837
[TBL] [Abstract][Full Text] [Related]
19. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
[TBL] [Abstract][Full Text] [Related]
20. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults.
Derry CJ; Derry S; Moore RA
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD009663. PubMed ID: 22336867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
